Trends in Prescription Drug Expenditures by Medicaid Enrollees
Bibliographic Data
| ID | 9100438 |
|---|---|
| Authors | Jessica S Banthin (Agency for Healthcare Research and Quality), G Edward Miller (0000-0001-8862-9177, Agency for Healthcare Research and Quality) |
| Year | 2006 |
| Volume | 44 |
| Issue | 5 |
| Pages | 27-35 |
| Publication date | 2006-05-01 |
| Peer Reviewed | Yes |
| Open Access | No |
| Type | ARTICLE |
| Venue | Medical Care (JOURNAL) |
| Journal identifiers | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Publisher | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/01.mlr.0000208132.36055.84 |
| PMID | 16625061 |
| OpenAlex | W2001237943 |
| Language | EN |
| Citations received | 4 |
| References cited | 10 |
OBJECTIVE: As prescription drug expenditures consume an increasingly larger portion of Medicaid budgets, states are anxious to control drug costs without endangering enrollees' health. In this report, we analyzed recent trends in Medicaid prescription drug expenditures by therapeutic classes and subclasses. Identifying the fastest growing categories of drugs, where drugs are grouped into clinically relevant classes and subclasses, can help policymakers decide where to focus their cost containment efforts. METHODS: We used data from the Medical Expenditure Panel Survey linked to a prescription drug therapeutic classification system, to examine trends between 1996/1997 and 2001/2002 in utilization and expenditures for the noninstitutionalized Medicaid population. We separated aggregate trends into changes in population with use and changes in expenditures per user, and percent generic. We also highlighted differences within the Medicaid population, including children, adults, disabled, and elderly. RESULTS: We found rapid growth in expenditures for antidepressants, antipsychotics, antihyperlipidemics, antidiabetic agents, antihistamines, COX-2 inhibitors, and proton pump inhibitors and found evidence supporting the rapid take-up of new drugs. In some cases these increases are the result of increased expenditures per user and in other cases the overall growth also comes from an increase in the population with use. CONCLUSIONS: Medicaid programs may want to reassess their cost-containment policies in light of the rapid take-up of new drugs. Our analysis also identifies areas in which more information is needed on the comparative effectiveness of new versus existing treatments
Drug · Drug Utilization Review · Economic growth · Environmental health · Health care · Health insurance · Medicaid · Medical Expenditure Panel Survey · Medical prescription · Population · Prescription drug · Health Systems, Economic Evaluations, Quality of Life · Medication Adherence and Compliance · Medicine · Pharmaceutical Economics and Policy · Pharmacology
Assessment of Adherence to and Persistence on Disease-Modifying Antirheumatic Drugs (DMARDs) in Patients With Rheumatoid Arthritis
Impact of Restricted Reimbursement on the Use of Statins in Finland
Improving Psychotherapeutic Medication Prescribing in Florida
Trends in Medical Care Costs, Coverage, Use, and Access
| Unique citing works | 4 |
|---|---|
| Citations per year | 0,2 |
| Citation span | 2006 - 2012 (7) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 1 |